(IQV) IQVIA Holdings - Ratings and Ratios
Clinical Research, Analytics, Consulting, Outsourcing, Intelligence
IQV EPS (Earnings per Share)
IQV Revenue
Description: IQV IQVIA Holdings October 14, 2025
IQVIA Holdings Inc. (NYSE:IQV) delivers an integrated suite of clinical research, commercial insight, and healthcare intelligence services to life-science and health-care firms across the Americas, Europe, Africa, and Asia-Pacific.
The firm operates through three core segments: (1) **Technology & Analytics Solutions**, which provides cloud-based applications, real-world evidence platforms, and advanced-analytics consulting that help clients track prescription trends, sales performance, and promotional activity down to the zip-code and prescriber level; (2) **Research & Development Solutions**, offering end-to-end clinical-trial support, central-lab services, genomics, bioanalysis, and vaccine-biomarker capabilities; and (3) **Contract Sales & Medical Solutions**, focused on provider- and patient-engagement, scientific strategy, and medical-affairs execution for pharma, biotech, device, diagnostic, and consumer-health companies.
IQVIA’s strategic partnership with Sarah Cannon Research Institute enhances its clinical-trial optimization offering, reinforcing the company’s position as a leading outsourced R&D partner.
From a financial-performance perspective, IQVIA reported FY 2023 revenue of roughly **$13.5 billion**, up **~8 % YoY**, driven primarily by double-digit growth in its Technology & Analytics segment (≈12 % YoY) and steady expansion in contract sales services. The company’s operating margin hovered around **13 %**, reflecting the higher-margin nature of its data-analytics and cloud solutions. A key sector driver is the accelerating demand for **real-world evidence (RWE)** and AI-enabled drug-development tools, which the firm is capitalizing on through its expanding cloud platform serving over **2,000** life-science clients.
For deeper quantitative analysis of IQVIA’s valuation metrics, you may find ValueRay’s data platform a useful next step.
IQV Stock Overview
| Market Cap in USD | 34,809m |
| Sub-Industry | Life Sciences Tools & Services |
| IPO / Inception | 2013-05-09 |
IQV Stock Ratings
| Growth Rating | -13.2% |
| Fundamental | 58.5% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -18.1% |
| Analyst Rating | 4.30 of 5 |
IQV Dividends
Currently no dividends paidIQV Growth Ratios
| Growth Correlation 3m | 54.2% |
| Growth Correlation 12m | -36.7% |
| Growth Correlation 5y | -27.9% |
| CAGR 5y | 3.17% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.07 |
| CAGR/Mean DD 3y (Pain Ratio) | 0.19 |
| Sharpe Ratio 12m | -0.92 |
| Alpha | -25.38 |
| Beta | 1.325 |
| Volatility | 29.14% |
| Current Volume | 2027.1k |
| Average Volume 20d | 1496.8k |
| Stop Loss | 212.5 (-3.4%) |
| Signal | 0.11 |
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income (1.24b TTM) > 0 and > 6% of Revenue (6% = 942.0m TTM) |
| FCFTA 0.07 (>2.0%) and ΔFCFTA 0.10pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -7.82% (prev -6.59%; Δ -1.23pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.09 (>3.0%) and CFO 2.62b > Net Income 1.24b (YES >=105%, WARN >=100%) |
| Net Debt (13.66b) to EBITDA (3.35b) ratio: 4.08 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.84 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (173.2m) change vs 12m ago -6.02% (target <= -2.0% for YES) |
| Gross Margin 34.25% (prev 35.10%; Δ -0.85pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 57.06% (prev 57.41%; Δ -0.35pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 3.24 (EBITDA TTM 3.35b / Interest Expense TTM 688.0m) >= 6 (WARN >= 3) |
Altman Z'' 1.27
| (A) -0.04 = (Total Current Assets 6.34b - Total Current Liabilities 7.57b) / Total Assets 28.63b |
| (B) 0.23 = Retained Earnings (Balance) 6.58b / Total Assets 28.63b |
| (C) 0.08 = EBIT TTM 2.23b / Avg Total Assets 27.52b |
| (D) 0.25 = Book Value of Equity 5.70b / Total Liabilities 22.85b |
| Total Rating: 1.27 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 58.50
| 1. Piotroski 4.50pt = -0.50 |
| 2. FCF Yield 4.15% = 2.07 |
| 3. FCF Margin 12.80% = 3.20 |
| 4. Debt/Equity 2.72 = -0.34 |
| 5. Debt/Ebitda 4.08 = -2.50 |
| 6. ROIC - WACC (= 1.13)% = 1.41 |
| 7. RoE 19.96% = 1.66 |
| 8. Rev. Trend 87.22% = 6.54 |
| 9. EPS Trend -60.96% = -3.05 |
What is the price of IQV shares?
Over the past week, the price has changed by +6.88%, over one month by +17.95%, over three months by +13.22% and over the past year by -3.68%.
Is IQVIA Holdings a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of IQV is around 211.31 USD . This means that IQV is currently overvalued and has a potential downside of -3.91%.
Is IQV a buy, sell or hold?
- Strong Buy: 14
- Buy: 2
- Hold: 7
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the IQV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 221.8 | 0.9% |
| Analysts Target Price | 221.8 | 0.9% |
| ValueRay Target Price | 234.2 | 6.5% |
IQV Fundamental Data Overview October 15, 2025
P/E Trailing = 29.5043
P/E Forward = 15.6006
P/S = 2.2171
P/B = 6.0121
P/EG = 1.054
Beta = 1.325
Revenue TTM = 15.70b USD
EBIT TTM = 2.23b USD
EBITDA TTM = 3.35b USD
Long Term Debt = 14.18b USD (from longTermDebt, last quarter)
Short Term Debt = 1.31b USD (from shortTermDebt, last quarter)
Debt = 15.70b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 13.66b USD (from netDebt column, last quarter)
Enterprise Value = 48.47b USD (34.81b + Debt 15.70b - CCE 2.04b)
Interest Coverage Ratio = 3.24 (Ebit TTM 2.23b / Interest Expense TTM 688.0m)
FCF Yield = 4.15% (FCF TTM 2.01b / Enterprise Value 48.47b)
FCF Margin = 12.80% (FCF TTM 2.01b / Revenue TTM 15.70b)
Net Margin = 7.88% (Net Income TTM 1.24b / Revenue TTM 15.70b)
Gross Margin = 34.25% ((Revenue TTM 15.70b - Cost of Revenue TTM 10.32b) / Revenue TTM)
Gross Margin QoQ = 32.94% (prev 33.90%)
Tobins Q-Ratio = 1.69 (Enterprise Value 48.47b / Total Assets 28.63b)
Interest Expense / Debt = 1.16% (Interest Expense 182.0m / Debt 15.70b)
Taxrate = 17.65% (57.0m / 323.0m)
NOPAT = 1.83b (EBIT 2.23b * (1 - 17.65%))
Current Ratio = 0.84 (Total Current Assets 6.34b / Total Current Liabilities 7.57b)
Debt / Equity = 2.72 (Debt 15.70b / totalStockholderEquity, last quarter 5.78b)
Debt / EBITDA = 4.08 (Net Debt 13.66b / EBITDA 3.35b)
Debt / FCF = 6.80 (Net Debt 13.66b / FCF TTM 2.01b)
Total Stockholder Equity = 6.20b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.32% (Net Income 1.24b / Total Assets 28.63b)
RoE = 19.96% (Net Income TTM 1.24b / Total Stockholder Equity 6.20b)
RoCE = 10.93% (EBIT 2.23b / Capital Employed (Equity 6.20b + L.T.Debt 14.18b))
RoIC = 8.94% (NOPAT 1.83b / Invested Capital 20.53b)
WACC = 7.81% (E(34.81b)/V(50.51b) * Re(10.90%) + D(15.70b)/V(50.51b) * Rd(1.16%) * (1-Tc(0.18)))
Discount Rate = 10.90% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -3.06%
[DCF Debug] Terminal Value 68.82% ; FCFE base≈1.94b ; Y1≈1.96b ; Y5≈2.15b
Fair Price DCF = 142.5 (DCF Value 24.22b / Shares Outstanding 170.0m; 5y FCF grow 1.13% → 3.0% )
EPS Correlation: -60.96 | EPS CAGR: -59.80% | SUE: -4.0 | # QB: 0
Revenue Correlation: 87.22 | Revenue CAGR: 4.47% | SUE: 1.63 | # QB: 1
Additional Sources for IQV Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle